Jane Edwards
The Department of Health and Human Services has entered strategic partnerships with a Roche Group subsidiary and The Medicines Co. to develop antibiotics against multi-drug resistant infections.
HHS’ office of the assistant secretary for preparedness and response forged the partnerships with the two companies through other transaction authority under the Pandemic and All Hazards Preparedness Act of 2006, HHS said Wednesday.
Hoffmann-LaRoche will receive from the Biomedical Advanced Research and Development Authority approximately $35 million over a two-year period and more than $151.6 million over five years to continue development work on diagnostic tests that work to detect bacterial and viral infections as well as experimental antibiotics against infections linked to drug-resistant bacteria.
BARDA will provide The Medicines Co. $32 million in funds over a four-year term and over $132 million over five years to further develop Carbavance, an investigational drug designed to treat bacterial pneumonia acquired from ventilators and hospitals.
Each firm will also share in the development cost and provide resources in order to support marketing efforts for their product portfolios.
